Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Haemostasis|January 1, 1992
Pharmacokinetic considerations on Orgaran (Org 10172) therapyM Danhof, A de Boer, H N Magnani, et al.
Thrombosis and Haemostasis|August 1, 1991
Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteersA de Boer, M Danhof, A F Cohen, et al.
Annals of Neurology|March 1, 1984
Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic diseaseH Ten Cate, C P Henny, H R Büller, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 7, 1983
A novel assay for the quantitative determination of lipoprotein-X (LP-X) in serumE S Bos, A A van der Doelen, A E Denissen, et al.
European Journal of Clinical Investigation|December 1, 1978
Quantitative changes of serum lipoprotein-X after cholestyramine administration in infants with cholestatic biliary tract and liver diseaseJ R Poley, D B Caplan, H N Magnani, et al.
British Journal of Clinical Pharmacology|June 1, 1987
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in manI D Bradbrook, H N Magnani, H C Moelker, et al.
Lancet (London, England)|March 7, 1987
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic strokeA G Turpie, M N Levine, J Hirsh, et al.
Thrombosis and Haemostasis|January 23, 1992
Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoidJ A Hoek, M T Nurmohamed, K J Hamelynck, et al.
Pageof 2